The structural heart device market is expected to grow at a medium double digit CAGR to reach $15,671 million by 2024.
Structural heart devices has emerged as a new focus area of medical device manufacturers as the population of most developed and developing countries continue to become older and risk of cardiovascular diseases increase with aging. The cardiovascular diseases which also include structural heart diseases have become leading cause of death.
It is projected that, with newfound prosperity due to globalization and industrialization has led to changing lifestyle leading to increasing risk of younger people developing cardiovascular diseases.
The increased interest has led to development of new technologies and devices that are less invasive and address the need of treatment of patients who are considered too weak to withstand the trauma of an open heart surgery.
The structural heart device market is classified based on product, product type and geography. Structural heart devices by product are segmented into Repair devices and Replacement devices. Repair devices by product type is segmented into Surgical Heart Repair (Annuloplasty) and Transcatheter heart repair devices. Transcatheter heart repair devices are further classified as Valvuloplasty, Occluders, Transcatheter Mitral Valve Repair and Others (Chordal replacement in mitral valve repair, Transcatheter tricuspid valve repair and Ventricular remodelling). Replacement devices by product type are segmented into Surgical Valve Replacement and Transcatheter Valve Replacement. Surgical valve replacement devices are further sub-segmented into Mechanical valves and Tissue valves. Transcatheter Valve Replacement devices are sub-segmented into Transcatheter aortic valve replacement (TAVR), Transcatheter Mitral valve replacement (TMVR), Transcatheter pulmonary valve replacement (TPVR).
Structural heart devices by product are segmented into Repair devices and Replacement devices. The replacement devices segment held the largest market revenue in 2017 and expected to grow at a medium double digit CAGR from 2017 to 2024.
In structural heart repair devices segment, transcatheter repair device held the largest share in 2017 and is projected to grow at a strong double digit CAGR from 2017 to 2024.
Among transcatheter repair devices, Transcatheter mitral valve repair device held the largest share in 2017 and is projected to grow at a strong double digit CAGR from 2017 to 2024.
The Structural heart Replacement segment is dominated by Transcatheter valve replacement that held largest share in 2017 and expected to grow at a strong double digit CAGR from 2017 to 2024.
Among the Surgical valve replacement devices, Tissue valves held the largest share in 2017 and is expected to grow at a single digit CAGR from 2017 to 2024.
Among the Transcatheter valve replacement devices, Transcatheter Aortic Valve Replacement (TAVR) devices held the largest share and expected to grow at a medium double digit CAGR from 2017 to 2024 and Transcatheter Mitral Valve Replacement (TMVR) devices is expected to grow at a strong double digit CAGR from 2017 to 2024.
The structural eart devices market by geography is divided into North America (U.S., Others), Europe (Germany, Italy, France, Others), Asia-pacific (Japan, China, Korea, Others) and Rest of the World (Brazil, Rest of Latin America, Middle East and Others).
North America region held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024. Among North America countries, U.S. held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024.
Europe held the second largest share and is expected to grow at a medium double digit CAGR from 2017 to 2024. Among European countries, Germany held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024.
Asia-Pacific is expected to grow at a strong double digit CAGR from 2017 to 2024. Among APAC countries, Japan held the highest share in 2017 and is expected to grow at a strong double digit CAGR from 2017 to 2024.
RoW is expected to grow at a medium double digit CAGR from 2017 to 2024. Among RoW countries, Brazil held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024.
Some of the major players in structural heart devices market include Abbott laboratories (U.S.), Medtronic (Ireland), Boston Scientific (U.S.), Edward Lifesciences (U.S.), LivaNova (U.K.), Lepu Medicals (China), JenaValve Technologies GmbH (Germany), Braile biomedia (Brazil), Cryolife (U.S.), Labcore Laboratories Ltd (Brazil).
Balton Sp. z o.o.
Bard Peripheral Vascular, Inc.
Biostable Science and Engineering
Braile bio medica
Cardiac Dimensions, Inc.
Cephea valve technologies
Colibri Heart Valve, LLC
Cook medicals LLC
Cryo life, Inc.
Guided Delivery Systems, Inc.
Heart Leaflet Technologies
High Life medicals
JenaValve Technology GmbH
Labcor Laboratrios Ltda.
Medtentia International Ltd Oy
Micro Interventional Devices
NaviGate Cardiac Structures Inc.
NVT Med AG
Strait access technologies Pvt Ltd
The Phoenix Cardiac device Pvt Ltd
Thubrikar Aortic Valve, Inc.
Toray Industries, Inc.
TransCardiac Therapeutics, LLC
Transcatheter Technologies GmbH
Venus Medtech (Hangzhou) Inc.
W. L. Gore and Associates
Xuzhou Yatai Scientific Co. Ltd.
Key Topics Covered
1 Executive Summary
2 Introduction 2.1 Key Takeaways 2.2 Scope Of The Report 2.3 Report Description 2.4 Markets Covered 2.5 Stakeholders 2.6 Research Methodology 2.6.1 Market Size Estimation 2.6.2 Market Breakdown And Data Triangulation 2.6.3 Secondary Sources 2.6.4 Primary Sources 2.6.5 Key Data Points From Secondary Sources 2.6.6 Key Data Points From Primary Sources 2.6.7 Assumptions
3 Market Analysis 3.1 Introduction 3.2 Market Segmentation 3.3 Factors Influencing Market 3.3.1 Drivers And Opportunities 18.104.22.168 Increase In Minimally Invasive Surgery For Structural Heart Diseases 22.214.171.124 Technology Advancements And Growing Healthcare Budgetary Allocation 126.96.36.199 Rising Geriatric Population With Structural Heart Diseases 188.8.131.52 Acquisitions To Open An Array Of Opportunities For The Market To Flourish 184.108.40.206 Vast Pipeline Products 3.3.2 Restraints And Threats 220.127.116.11 High Cost Of The Structural Heart Devices 18.104.22.168 Lack Of Patient Awareness And Healthcare Infrastructure In Developing Countries 22.214.171.124 Stringent Regulatory Guidelines 126.96.36.199 Lack Of Skilled And Trained Professionals 3.4 Regulatory Affairs 3.4.1 International Organization For Standardization 188.8.131.52 Iso 9001: 2015 Quality Management System 184.108.40.206 Iso 13485 Medical Devices 220.127.116.11 Iso 10993 Biological Evaluation Of Medical Devices 3.4.2 U.S. 3.4.3 Canada 3.4.4 Europe 3.4.5 Japan 3.4.6 China 3.4.7 India 3.5 Reimbursement Scenario 3.5.1 Reimbursement Table 3.6 Patent Trends 3.7 Technological Advancements 3.7.1 Introduction 3.7.2 Tissue Engineering 3.7.3 Polymeric Heart Valves 3.7.4 Sutureless Aortic Valve Replacement (SU-AVR) System 3.7.5 Endoscopic Aortic Valve Replacement (TEVAR) System 3.7.6 3-D Printed Model 3.8 Clinical Trials 3.9 Porter'S Five Force Analysis 3.9.1 Threat Of New Entrants 3.9.2 Threat Of Substitutes 3.9.3 Bargaining Power Of Suppliers 3.9.4 Bargaining Power Of Buyers 3.9.5 Competitive Rivalry 3.10 Supply Chain Analysis 3.11 Market Share Analysis By Major Players 3.11.1 Structural Heart Devices Global Market Share Analysis 3.11.2 Market Share Analysis Of Annuloplasty Repair Devices By Major Players 3.11.3 Market Share Analysis Of Occluders By Major Players 3.11.4 Market Share Analysis Of Mechanical Valve Replacement Devices By Major Players 3.11.5 Market Share Analysis Of Tissue Valve Replacement Devices By Major Players 3.11.6 Market Share Analysis Of Transcatheter Aortic Valve Replacement By Major Players 3.12 Structural Heart Diseases U.S. Market Penetration, Prevalence, Opportunity And Number Of Procedures Performed 3.13 Structural Heart Devices Number Of Units By Region 3.13.1 Occluders Number Of Units By Region 3.13.2 Transcatheter Mitral Valve Repair Devices Number Of Units By Region 3.13.3 Surgical Valve Repari - Annuloplasty Devices Number Of Units By Region 3.13.4 Transcatheter Aortic Valve Replacement (TAVR) Devices Number Of Units By Region 3.13.5 Transcatheter Mitral Valve Replacement (TMVR) Devices Number Of Units By Region 3.13.6 Transcatheter Pulmonary Valve Replacement (TPVR) Devices Number Of Units By Region 3.14 Structural Heart Devices Company Comparison Table By Products 3.14.1 Aortic Valve Devices Company Comparison Table By Products 3.14.2 Mitral Valve Devices Company Comparison Table By Products 3.14.3 Closure Devices (Occluders) Company Comparison Table By Products 3.14.4 Other Structural Heart Devices Company Comparison Table By Products
5 Regional Analysis 5.1 Introduction 5.2 North America 5.2.1 U.S. 5.2.2 Others 5.3 Europe 5.3.1 Germany 5.3.2 Italy 5.3.3 France 5.3.4 Others 5.4 Apac 5.4.1 Japan 5.4.2 China 5.4.3 Korea 5.4.4 Others 5.5 Row 5.5.1 Brazil 5.5.2 Rest Of Latam 5.5.3 Middle East & Others
6 Competitive Landscape 6.1 Introduction 6.2 Approvals 6.3 Acquisitions 6.4 New Product Launch 6.5 Agreements 6.6 Other Developments